U.S. Markets open in 2 hrs 16 mins

CTI BioPharma Corp. (CTIC)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.18+0.01 (+0.24%)
At close: 4:00PM EDT
People also watch
AGENHEBXOMAKERXGERN

CTI BioPharma Corp.

3101 Western Avenue
Suite 600
Seattle, WA 98121
United States
206-282-7100
http://www.ctibiopharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees104

Key Executives

NameTitlePayExercisedAge
Dr. Jack W. Singer M.D.Co-Founder, Chief Scientific Officer, Global Head-Translational Med, Interim CMO & Exec Director522.99kN/A74
Mr. Bruce J. SeeleyPrincipal Financial Officer, Chief Commercial & Admin. Officer, Exec. VP and Sec.503.35kN/A53
Dr. Matthew James Plunkett Ph.D.Chief Bus. Officer and Exec. VP499.31kN/A45
Dr. Adam R. Craig M.D., Ph.D., M.B.A.Chief Exec. Officer, Pres and DirectorN/AN/A51
Dr. Silvano SpinelliExec. VP of Devel. and Managing Director of European OperationsN/AN/A64
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreement with the University of Vermont, BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Corporate Governance

CTI BioPharma Corp.’s ISS Governance QualityScore as of May 1, 2017 is 9. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.